• ProteinQure

  Led · Series A · May 2025

  ProteinQure develops AI-driven peptide therapeutics using a proprietary ProteinStudio platform that integrates machine learning, structural biology, and atomic-level simulations to design peptides with non-natural amino acids for tissue-specific delivery. Its lead candidate, PQ203, is a first-in-class peptide-drug conjugate targeting the sortilin receptor and is being developed for triple-negative breast cancer and tumors resistant to topoisomerase I inhibitors. Preclinical efficacy was demonstrated in patient-derived xenograft models. The company plans a multicenter phase 1 trial for PQ203 anticipated to open in Q3 2025 with planned enrollment of 70–100 patients across Canada and the U.S., at centers including Princess Margaret, MD Anderson, and Yale Cancer Center. ProteinQure is advancing additional pipeline programs in neurology and nephrology and is pursuing partnerships with global biopharma to accelerate its platform. The company is headquartered in Toronto and has combined seed and Series A funding of $16 million. ProteinQure is a Toronto-based protein therapeutics company that develops computational R&D tools for in silico drug design. Its platform leverages quantum computing, molecular simulations and reinforcement learning to engineer novel therapeutics. The platform combines biophysical models with statistical and machine learning approaches and leverages high-performance GPUs, TPUs, specialized circuits and quantum computers. It also integrates experimental data and assays to complement the computational models, allowing the company to learn complex underlying relationships and scale simulations. ProteinQure has begun applying the platform in initial collaborations with industry leaders in the discovery of protein therapeutics and plans to work with these teams over the next two years to generate additional data on peptide drug discovery. The company raised $4M in seed funding to continue adding interdisciplinary talent and expand partnerships with industry leaders.

• Aifleet

  Led · Series B · Sep 2024

  Aifleet provides a proprietary AI algorithm and technology suite for trucking operations, including dynamic pricing tools, a modernized in-house TMS, real-time tracking, and driver-centric scheduling. The company manages 20 quintillion permutations per truck per week, which it says equates to 250K loads per week and $20 billion in orders per year. Aifleet plans to use new capital to expand technology research and development, grow its operations team to support the fleet at scale, expand its sales organization, and further develop scalable infrastructure and processes. Leadership is headed by CEO Marc El Khoury and the company is based in Austin, TX. The firm also intends to bring AI-adjacent use cases to the industry and, in the future, operationalize electric and autonomous technologies. The business appears focused on scaling both its technical platform and operational capabilities to support larger volumes and more complex routing and pricing scenarios.

• Heard Technologies

  Participated · Series A · Jun 2023

  Heard provides an all-in-one financial solution for therapists, combining software and human support to handle bookkeeping, taxes, payroll, and other back-office tasks. The product targets independent practitioners who, amid a surge in telehealth and digital care delivery, are starting their own practices and need help managing business operations. Therapists often spend 20–30 hours weekly on client sessions and paperwork, and many seek reduced mental burden and more breathing room rather than new clients. The company plans to continue product development with a focus on improving bookkeeping, payroll, and tax workflows, and is hiring leadership including a VP of Engineering and a Head of Tax Operations. Heard has brought on leaders such as COO KK Mulligan and support leader Brandon Wolf to support scale in regulated environments. Financially, Heard has raised $26.3 million to date, including $15 million in its most recent round.

• Guava

  Led · Seed · Jul 2022

  Guava is a mobile-first, connected banking and networking platform built by and for Black entrepreneurs. The platform combines digital banking features with an expansive community where entrepreneurs can connect, learn, and partner. Founder and CEO Kelly Ifill leads the company. Guava raised $650K as an extension of its pre-seed round. The company intends to use the funds to expand the product and its community aspects, supporting insights and sharing best practices with customers. Guava is based in New York. Guava offers digital banking services and a community platform built to address the specific needs of Black entrepreneurs, tackling the racial wealth gap by facilitating development, growth and resilience of small businesses. The company provides a combined banking and networking product aimed at creators and small business owners. Guava intends to use its newly raised funds to accelerate growth and expand operations. Founded and led by CEO Kelly Ifill in 2021, the company has pursued partnerships and recognition to grow its reach. Guava was selected for Mastercard’s Start Path startup engagement program and won first place in the NYC Recovery Challenge with Google, Cornell Tech and Tech: NYC. The recent $2.4M financing will support scaling of its product and community efforts.

• wavepaths

  Participated · Seed · Nov 2021

  Wavepaths builds on scientific research showing the critical role of music in psychedelic therapy, offering clinicians an AI-powered system that generates personalized, adaptive soundscapes in real time. Practitioners can seamlessly shift emotional atmospheres, depth, activation levels and instrumentation, drawing on compositions from artists such as Jon Hopkins, Greg Haines, Robert Rich and Christina Vantzou. Founded in 2019 by Dr. Mendel Kaelen and Anna Rickman, the company partners with research institutions, universities and psychedelic-therapy providers to study and optimize therapeutic outcomes. The product is currently in closed beta, is used in more than 29 countries and has a wait-list exceeding 5,000 practitioners ahead of a planned public launch later this year. Fresh capital will be deployed to refine the platform’s personalization and music-generation algorithms, scale infrastructure and add features for a broader range of healthcare practices.

No current team members are available.